Pages that link to "Q33786150"
Jump to navigation
Jump to search
The following pages link to An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. (Q33786150):
Displaying 50 items.
- Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future (Q26752699) (← links)
- A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide (Q26796417) (← links)
- Adverse Effects of GLP-1 Receptor Agonists (Q26801346) (← links)
- Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors (Q27021870) (← links)
- Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes (Q28067465) (← links)
- A β-peptide agonist of the GLP-1 receptor, a class B GPCR. (Q33553641) (← links)
- Glycemic control: a combination of lifestyle management and the use of drugs (Q33936137) (← links)
- Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates (Q34219669) (← links)
- Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications. (Q35087846) (← links)
- Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy (Q35667150) (← links)
- GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities (Q36153247) (← links)
- Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center (Q36285880) (← links)
- The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide (Q36368988) (← links)
- Potential use of exenatide for the treatment of obesity (Q36391466) (← links)
- Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4 (Q36439654) (← links)
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. (Q36584204) (← links)
- Hydrogel drug delivery system with predictable and tunable drug release and degradation rates (Q36598151) (← links)
- Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control (Q36637567) (← links)
- A review of the hypoglycemic effects of five commonly used herbal food supplements (Q36766202) (← links)
- Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature (Q36872178) (← links)
- Glucagon-like peptide-1 analogues: An overview (Q37015969) (← links)
- Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). (Q37106572) (← links)
- Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin (Q37119965) (← links)
- Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. (Q37295993) (← links)
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists (Q37340223) (← links)
- Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus (Q37410215) (← links)
- How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment (Q37577129) (← links)
- Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics (Q37895271) (← links)
- From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy (Q37900151) (← links)
- Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes (Q37900626) (← links)
- Using albumin to improve the therapeutic properties of diabetes treatments (Q37910976) (← links)
- The future of incretin‐based therapy: novel avenues—novel targets (Q37913528) (← links)
- Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents (Q37929159) (← links)
- Liraglutide: clinical pharmacology and considerations for therapy (Q37933408) (← links)
- Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus (Q37993945) (← links)
- Drug-drug interactions with glucagon-like peptide-1 receptor agonists (Q38003273) (← links)
- Update on incretin hormones (Q38006504) (← links)
- Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings (Q38014516) (← links)
- Peptides and peptide conjugates: therapeutics on the upward path (Q38037191) (← links)
- Review article: a comparison of glucagon-like peptides 1 and 2. (Q38057350) (← links)
- Once weekly exenatide: efficacy, tolerability and place in therapy (Q38083112) (← links)
- Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus (Q38095813) (← links)
- The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications (Q38101677) (← links)
- Update on obesity pharmacotherapy (Q38196951) (← links)
- Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases (Q38197368) (← links)
- Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. (Q38212472) (← links)
- Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents (Q38214060) (← links)
- Therapies for inter-relating diabetes and obesity - GLP-1 and obesity (Q38254745) (← links)
- New molecular targets in the pathophysiology of obesity and available treatment options under investigation (Q38397535) (← links)
- Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes (Q38524435) (← links)